Target intelligence / Profile preview

Leucine-rich repeat and WD repeat-containing protein 1 (LRWD1)

Target
LRWD1
Molecular classification
Chromatin-binding protein, Cell cycle regulator, Heterochromatin organizer, Epigenetic regulator
01

Overview

Leucine-rich repeat and WD repeat-containing protein 1 (LRWD1) is a chromatin-associated protein with a leucine-rich repeat (LRR) domain and several WD40 repeats. LRWD1 functions primarily as a scaffold facilitating the recruitment and stabilization of the origin recognition complex (ORC) to chromatin during the G1 phase, which is critical for initiating DNA replication and ensuring proper cell cycle progression. LRWD1 also binds repressive histone marks (such as H3K9me3, H3K27me3, and H4K20me3) and methylated DNA, contributing to heterochromatin maintenance and gene silencing. In testicular tissue, LRWD1 expression is essential for normal spermatogenesis and sperm motility, partly due to its epigenetic regulation by promoter methylation. Aberrant LRWD1 activity or expression has been implicated in male infertility and is associated with certain cancers. Modulation of LRWD1 expression by epigenetic drugs (e.g., DNA methylation inhibitors) has been explored primarily in cellular models[1][2][3].

Other names
ORCACENP-33Origin recognition complex-associated proteinORC-associated proteinCentromere protein 33DKFZp434K1815testicular tissue protein Li 4
02

Mechanism of action

Modulation of DNA methylation status influences LRWD1 transcription and protein expression[1]. Drugs altering methylation (5-Aza-2′-deoxycytidine, floxuridine) do so indirectly via epigenetic regulation rather than direct binding[1].

03

Biological functions

DNA replication licensingHeterochromatin organizationG1/S cell cycle transitionRecruitment/stabilization of origin recognition complex (ORC) to chromatinBinding to methylated histones/DNASpermatogenesis regulation
04

Disease associations

Infertility (male infertility, defective spermatogenesis)Cancer (e.g., skin angiosarcoma, embryonal testis carcinoma)Potential involvement in Ewing sarcoma cell viability
05

Safety considerations

No direct-targeting small-molecule drugs or monoclonal antibodies known; thus, safety concerns specific to LRWD1 inhibition/modulation are not definedGeneral epigenetic drug risks (e.g., off-target demethylation) apply to drugs affecting LRWD1 expression
06

Interacting drugs

5-Aza-2′-deoxycytidine (DNA methylation inhibitor)

1 more in the full profile.

07

Biomarkers

LRWD1 promoter methylation status (proposed as marker for male infertility or sperm quality)LRWD1 expression level (proposed as biomarker in testicular dysfunction/spermatogenesis)

Beyond the preview

Go deeper on Leucine-rich repeat and WD repeat-containing protein 1 (LRWD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leucine-rich repeat and WD repeat-containing protein 1 (LRWD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call